Safety Evaluation of ABX464 in Patients With Moderate to Severe Active Crohn's Disease
Status:
Not yet recruiting
Trial end date:
2021-10-30
Target enrollment:
Participant gender:
Summary
This Phase IIa study is a 16-week, double-blind, placebo-controlled, randomized study aiming
at evaluating the safety and the efficacy of ABX464 given once a day (o.d) at 50 mg in
subjects with moderate to severe active Crohn's Disease who have inadequate response, loss of
response, or intolerance to prior amino-salicylates, immunosuppressant treatment, biologics,
and/or corticosteroid treatment, and followed by a 4 weeks period of follow-up after the last
study drug intake.